ClinicalTrials.gg
Enrolling by invitationNCT04553276UKSARUpdated Oct 7, 2026

Co-morbidity and Refractory Asthma - UK Severe Asthma Registry

An observational study in Asthma, sponsored by Queen's University, Belfast. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Queen's University, Belfast · Observational

How we know

Updated Oct 7, 2026Now Enrolling by invitationPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
4,800
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.

Planned enrollment
15th of 131
4,800 · median 149
Started
2020
with 14 others
Observational
131 of 558
24 open now
Primary completion
2030-08
later than 65 of 70 live
Registered
418th of 558
by date

Among the 558 studies in Asthma with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 131 observational ones that give a count, is one of 15 that started in 2020, is one of 131 observational ones, reaches primary completion later than 65 of the 70 other live ones, and was the 418th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Asthma with a site in United Kingdom, or all of them as a file.
02

Study summary

A "Clinical Registry" is a database which contains clinical information about people with different medical conditions. They are used in many countries throughout the world to help medical teams to better understand specific diseases and improve the care and treatment of patients.

The UK Severe Asthma Registry has been collecting data on patients attending Severe Asthma Clinics in the UK since 2007.

After obtaining appropriate consent from patients to use their information, data is entered by the patient's own clinical team and it is kept up-to-date to follow clinical progress and response to treatments. Very strict controls are in place to make sure individuals cannot be identified from the Registry and all information available from the National Registry is anonymous.

Apart from the local clinic team, occasionally trusted third parties will also be able to identify you, if required to do so, on a strict need-to-know basis. This is necessary to ensure that the Registry works efficiently, or as a part of a Research Project, previously approved by a Research Ethics Committee.

Data from the Registry has a number of uses including judging which severe asthma treatments are of greater benefit, to identify different subgroups of severe asthma and trial new therapies and to provide information for planning future services for people with severe asthma. The use of any information from the UK Severe Asthma Registry requires approval of the Steering Committee which is made up of the refractory asthma specialists from across the UK and who will have access to data protection, legal and ethics expertise where necessary, to safeguard the use of data.

If the Registry closes, data will be returned to the local clinic team if requested, otherwise it will be destroyed. Participation is entirely voluntary and patients can withdraw consent form the Registry at any time by informing their local clinical team. The Data Controller from the UK Severe Asthma Registry is Queen's University Belfast and the Data Processor is Dendrite Clinical Services Ltd which is a commercial provider of database and registry systems.

Read the detailed description

There are currently 14 Networks of UK dedicated Specialist Difficult Asthma Services submitting data to the UK Registry: Belfast City Hospital; Royal Brompton \& Harefield, London; Birmingham Regional Severe Asthma Service; South Thames \& Kent Severe Asthma Service; East Midlands Severe Asthma Network; North West Midlands Severe Asthma Service; Yorkshire Asthma MDT; East of England Severe Asthma Network; Wessex Severe Asthma Network; South West Asthma Network; North West Asthma Network, Newcastle Severe Asthma Network and Greater Glasgow \& Clyde.

The Registry was set up to standardise clinical services in the UK and facilitate research into patients with difficult asthma. Patients that attend difficult asthma services across the UK are approached to give consent for inclusion. The Registry is hosted online by Dendrite Clinical Systems and admits password protected anonymised data, after fully informed written consent is obtained from patients (see Patient Information and Consent sheets). The individual centre data can be downloaded locally by registered users for audit purposes. The Registry records patient demographics including gender, age at diagnosis, race, occupation, smoking status, BMI. Disease characteristics such as asthma medication, unscheduled healthcare visits, exacerbations, hospital and ICU admissions, blood and sputum investigations, allergen testing, pulmonary function are also recorded in the registry.

Subjects have been entered into the Registry in a non-selected manner and there are currently over 4800 subjects in the Registry with detailed demographic, disease characteristics and health outcome data. Of these subjects, the majority after detailed assessment fulfil the American Thoracic Society definition of refractory asthma, whilst others after detailed assessment are identified as having non-refractory asthma.

The Registry has also been expanded to collect data on bronchial thermoplasty in line with NICE Guidance on bronchial thermoplasty for severe asthma (http://www.nice.org.uk/guidance/ipg419).

the Registry with detailed demographic, disease characteristics and health outcome data.

As part of NHS England Central Commissioning for Specialist Severe Asthma Services, all specialist centres in the UK will be required to input data into the Registry to enable benchmarking between centres.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients that are referred to specialist severe asthma services across the UK. The majority of patients after detailed assessment fulfill the American Thoracic Society definition of refractory asthma, whilst others after detailed assessment are identified as having non-refractory asthma.

Eligibility criteria

Inclusion Criteria:

1. Referral to a specialist severe asthma clinic in the UK due to inadequate asthma control

Exclusion Criteria: None

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
4,800 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Proportion of patients with no systemic corticosteroid exposure in most recent 12 month follow-up period

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Aug 2030, 120 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 120 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2025 → Aug 2030 and completion Aug 2025 → Aug 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2020
First posted
Sep 17, 2020
StartActual
Aug 26, 2020
Primary completionEst.
Aug 26, 2030was Aug 2025
CompletionEst.
Aug 26, 2030was Aug 2025
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 7, 2026
Primary completion
Aug 26, 2025→Aug 26, 2030
Oct 7, 2026
Study completion
Aug 26, 2025→Aug 26, 2030
Oct 7, 2026
Contact
No study contact listed any more: removed l•••@qub.ac.uk · •••6376
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Enrolling by invitation
    Primary completion Aug 26, 2025→Aug 26, 2030
    Study completion Aug 26, 2025→Aug 26, 2030
    Contact No study contact listed any more: removed l•••@qub.ac.uk · •••6376
    + 5 other changes: verification date, criteria formatting, site details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04553276
Collaborators
Royal Brompton & Harefield NHS Foundation Trust, University Hospital Birmingham NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Barts & The London NHS Trust, University Hospitals, Leicester, Nottingham University Hospitals NHS Trust, University Hospitals of North Midlands NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust, Hull University Teaching Hospitals NHS Trust, The Leeds Teaching Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, Oxford University Hospitals NHS Trust, University Hospital Plymouth NHS Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Devon and Exeter NHS Foundation Trust, Taunton and Somerset Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, NHS Greater Glasgow and Clyde
Responsible party
Liam Heaney (Professor of Respiratory Medicine, Queen's University, Belfast) — Principal investigator
First posted
Sep 17, 2020
Start date
Aug 26, 2020
Primary completion
Aug 26, 2030 (estimated)
Completion
Aug 26, 2030 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion